Mycobacterium tuberculosisMicrobiologic and Clinical Treatment Outcomes in a Randomized Trial of Immediate versus CD4+‐Initiated Antiretroviral Therapy in HIV‐Infected Adults with a High CD4+Cell Count
Author(s) -
Gabriel Chamie,
Edwin D. Charlebois,
Padmini Srikantiah,
Maria Walusimbi-Nanteza,
Roy D. Mugerwa,
Harriet MayanjaKizza,
Alphonse Okwera,
Christopher C. Whalen,
Diane V. Havlir
Publication year - 2010
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1086/654799
Subject(s) - medicine , tuberculosis , sputum , mycobacterium tuberculosis , randomized controlled trial , directly observed therapy , sida , clinical trial , antiretroviral therapy , human immunodeficiency virus (hiv) , immunology , viral disease , viral load , pathology
In a prospective randomized, controlled trial in Uganda comparing the efficacy of antiretroviral therapy during tuberculosis therapy with the efficacy of tuberculosis therapy alone in HIV-infected patients with tuberculosis who have a CD4(+) cell count >350 cells/microL, it was found that antiretroviral therapy did not accelerate microbiologic, radiographic, or clinical responses to tuberculosis therapy: 18% of participants had sputum smears positive for Mycobacterium tuberculosis after 5 months of tuberculosis therapy, despite having had negative culture results. Trial registration. ClinicalTrials.gov identifier: NCT00078247 .
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom